Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis

Harris, Violaine K.; Faroqui, Raihan; Vyshkina, Tamara; Sadiq, Saud

doi:10.5966/sctm.2012-0015

Cited by 62 publications

(61 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protocol has been tested in nonhuman primates and human patients who receive intravenous injections of their own BMSCs (34,40,46). The results show neuroprotection, neurotrophic effects, and anti-inflammatory responses after transplantation therapy (20,22). In preclinical laboratories, BMSCs have been considered a promising cell source for treatment of many diseases, including ischemic stroke (15,63), traumatic brain injury (60), intracerebral hemorrhage (62), subarachnoid hemorrhage (31), spinal cord injury (33), and other neurodegenerative disorders (2,29,39,42).…”

Section: Discussionmentioning

confidence: 99%

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Wei

Ferdinand

et al. 2015

Cell Transplant

View full text Add to dashboard Cite

Neonatal stroke is a major cause of mortality and long-term morbidity in infants and children. Currently, very limited therapeutic strategies are available to protect the developing brain against ischemic damage and promote brain repairs for pediatric patients. Moreover, children who experienced neonatal stroke often have developmental social behavior problems. Cellular therapy using bone marrow mesenchymal stem cells (BMSCs) has emerged as a regenerative therapy after stroke. In the present investigation, neonatal stroke of postnatal day 7 (P7) rat pups was treated with noninvasive and brain-specific intranasal delivery of BMSCs at 6 h and 3 days after stroke (1 × 10 6 cells/animal). Prior to transplantation, BMSCs were subjected to hypoxic preconditioning to enhance their tolerance and regenerative properties. The effects on regenerative activities and stroke-induced sensorimotor and social behavioral deficits were specifically examined at P24 of juvenile age. The BMSC treatment significantly reduced infarct size and blood-brain barrier disruption, promoted angiogenesis, neurogenesis, neurovascular repair, and improved local cerebral blood flow in the ischemic cortex. BMSC-treated rats showed better sensorimotor and olfactory functional recovery than saline-treated animals, measured by the adhesive removal test and buried food finding test. In social behavioral tests, we observed functional and social behavioral deficits in P24 rats subjected to stroke at P7, while the BMSC treatment significantly improved the performance of stroke animals. Overall, intranasal BMSC transplantation after neonatal stroke shows neuroprotection and great potential as a regenerative therapy to enhance neurovascular regeneration and improve functional recovery observed at the juvenile stage of development.

show abstract

Section: Discussionmentioning

confidence: 99%

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Wei

Ferdinand

et al. 2015

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…On another tone, MSC transplantations used for tissue repair purposes and transplantations have been performed for the treatment of skeletal fractures, osteoarthritis, cancer, hemorrhages, liver failure, ischemic heart failure, and chronic otitis, among others. [74][75][76][77][78][79] Recent systematic review papers based on meta-analysis data suggest that transplantation of bone marrow MSCs in patients with acute myocardial infarction or chronic ischemic heart disease is safe and associated with slight improvement in left ventricular function, left ventricular end systolic volume, and decreased infarct size when compared to state of the art therapy. 80,81 However, both meta-analyses suggested that individual trials have not yet been large enough to reliably explore the outcomes.…”

Section: Mscs In Clinical Trialsmentioning

confidence: 99%

Mesenchymal Stromal Cell Therapy

et al. 2015

View full text Add to dashboard Cite

“…In addition, placental MSCs via reduced production of the anti-inflammatory proteins such as TNF-α-stimulated gene/ protein 6 (TSG-6) in inflammatory regions, have therapeutic effects in mice with EAE [19]. Other studies have shown the therapeutically benefit of BM-MSCs [20,21] In contrast with these studies, Nessler et al, showed that intravenously administration of human BM-MSCs has no effects on remyelination process and glial cell reactions in cuprizone model of MS because these cells were not able to cross the blood-brain barrier [26]. Thus, adipose-derived stem cell (ADSCs) as a suitable cell source has attracted attention…”

Section: Stem Cells Transplantation In Demyelinating Diseasesmentioning

confidence: 99%

Therapeutic effects of adipose derived mesenchymal stem cells on remyelination process in inflammatory demyelinating diseases

Ghasemi¹

2015

J Histol Histopathol

View full text Add to dashboard Cite

Multiple sclerosis "MS" is a frequent demyelinating disease that affecting the central nervous system and associated with a progressive clinical course or severe disability in young adults. This narrative review summarizes the comprehensive information about adipose derived mesenchymal stem cells as one of the best sources for cell based therapy in demyelinating disease. The precise cause of MS is unknown, but the current evidence suggests that it can be linked to both genetic predisposition and environmental factors. During this abnormal condition, multifocal zones of inflammation due to focal immune cells infiltration and vascular abnormalities as well as change in plasmalemma permeability can occur which may are the primary cause of myelin sheath destruction. In addition to this pathological change, the formations of central nerve system plaques can also occur which crosstalk with the correct transmission of nerve impulse and finally lead to neuronal dysfunction. Conventional drug therapies for MS are not able to stop the degeneration of nerve tissue. So, stem cell based therapies has been proposed for the treatment of MS. In this narrative review, some of the characteristics and therapeutic effects of adipose-derived stem cells as a suitable cell source for cell transplantation in MS disease have been discussed.

show abstract

Characterization of Autologous Mesenchymal Stem Cell-Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis

Abstract: ABSTRACT

Cited by 62 publications

References 51 publications

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Mesenchymal Stromal Cell Therapy

Therapeutic effects of adipose derived mesenchymal stem cells on remyelination process in inflammatory demyelinating diseases

Contact Info

Product

Resources

About